Saturday, October 31, 2026

GBP/EUR Bullish Momentum With A 1% Jump In The Last 21 Sessions

GBP/EUR Bullish Momentum With A 1% Jump In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.52% for the last 21 sessions. At 14:07 EST on Wednesday, 14 June, GBP/EUR (GBPEUR) is $1.17.

GBP/EUR's yearly highs and lows, it's 8.138% up from its 52-week low and 2.469% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.03%, 0.07%, and 0.24%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.35% (last week), 0.22% (last month), and 0.24% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy edges upward as US bond yields propel gains amid fed-boj’s decisions. According to FXStreet on Monday, 12 June, "However, from a medium-term view, with the daily Exponential Moving Averages (EMAs) positioned below the spot price, the pair is upward, but it needs to crack the top of the range, so the USD/JPY can test the year-to-date (YTD) high of 140.92. ", "In the case of being broken, the USD/JPY next stop is 141.00, ahead of the November 22 high at 142.24. "
  • Usd/jpy ignores downbeat Japan ppi, boj’s wakatabe to drop toward 139.00, focus on US inflation, fed. According to FXStreet on Monday, 12 June, "Amid these plays, US Treasury bond yields struggle to extend the previous week's upward trajectory while S&P500 Futures manage to trace Wall Street's gains, which in turn should put a floor under the USD/JPY pair due to the quote's risk-barometer status.", "Moving on, a light calendar on Monday may restrict intraday moves of the USD/JPY pair. "
  • Usd/jpy prods yen bears near 139.50 as yields retreat, risk dwindles ahead of US inflation. According to FXStreet on Tuesday, 13 June, "Even so, the increase in the bets favoring the Federal Reserve's (Fed) 0.25% rate hike in July prod the sentiment and put a floor under the US Dollar, as well as the USD/JPY price. ", "Moving on, the bond market moves and risk catalysts will be important to determine the short-term moves of the USD/JPY pair. "
  • Usd/jpy: tight higher range displaying conservative approach - 13 June 2023. According to DailyForex on Tuesday, 13 June, "In fact, it can be argued the USD/JPY has experienced a rather consolidated higher value since the 25th of May. ", "As of this writing the USD/JPY is trading near the 139.500 vicinity with seemingly rather comfortable results being displayed. "
  • Usd/jpy remains depressed below mid-139.00s, downside seems limited ahead of US CPI. According to FXStreet on Tuesday, 13 June, "This is seen as another factor that contributes to the offered tone surrounding the USD/JPY pair. ", "Firming expectations that the Federal Reserve (Fed) will more likely skip hiking interest rates in June drags the US Dollar (USD) to its lowest level since May 22 and turns out to be a key factor dragging the USD/JPY pair lower. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com